{{Drugbox
| Watchedfields = changed
| verifiedrevid = 444576847
| IUPAC_name = 2-(3''H''-Inden-4-yloxymethyl)morpholine
| image = Indeloxazine.svg
| width = 200

<!--Clinical data-->
| tradename =  
| pregnancy_category =  
| legal_status = Discontinued

<!--Pharmacokinetic data-->
| bioavailability =  
| metabolism =  
| elimination_half-life = 
| excretion =

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 60929-23-9
| ATC_prefix = None
| ATC_suffix =  
| PubChem = 3704
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 3576
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 834M09R1KM
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D08077

<!--Chemical data-->
| C=14 | H=17 | N=1 | O=2 
| molecular_weight = 231.290 g/mol
| smiles = O(c1cccc2\C=C/Cc12)CC3OCCNC3
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C14H17NO2/c1-3-11-4-2-6-14(13(11)5-1)17-10-12-9-15-7-8-16-12/h1-4,6,12,15H,5,7-10H2
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = MADRVGBADLFHMO-UHFFFAOYSA-N
| synonyms = CI-874, YM-08054
}}

'''Indeloxazine''' ([[International Nonproprietary Name|INN]]) ('''Elen''', '''Noin''') is an [[antidepressant]] and [[cerebral activator]]<ref name="pmid4092278">{{cite journal |vauthors=Kojima T, Niigata K, Fujikura T | title = Syntheses of (+/-)-2-[(inden-7-yloxy)methyl]morpholine hydrochloride (YM-08054, indeloxazine hydrochloride) and its derivatives with potential cerebral-activating and antidepressive properties | journal = Chemical & Pharmaceutical Bulletin | volume = 33 | issue = 9 | pages = 3766–74 | date = September 1985 | pmid = 4092278 | doi = 10.1248/cpb.33.3766| url = |display-authors=etal}}</ref><ref name="pmid6841538">{{cite journal |vauthors=Hayes AG, Chang T | title = Determination of indeloxazine, a new antidepressant agent, in human plasma by gas-liquid chromatography with electron-capture detection | journal = Journal of Chromatography | volume = 272 | issue = 1 | pages = 176–80 | date = January 1983 | pmid = 6841538 | doi = 10.1016/s0378-4347(00)86115-0| url = }}</ref> that was marketed in [[Japan]] and [[South Korea]] by [[Yamanouchi Pharmaceutical Co., Ltd]] for the treatment of [[mental disorder|psychiatric symptom]]s associated with [[cerebrovascular disease]]s, namely [[depression (mood)|depression]] resulting from [[stroke]], [[emotional dysregulation|emotional disturbance]], and [[avolition]].<ref name="urlIndex nominum, international drug ... - Google Books">{{cite book | url = https://books.google.com/?id=5GpcTQD_L2oC&lpg=PA548&dq=indeloxazine&pg=PA548#v=onepage&q=indeloxazine&f=false | title = Index nominum, international drug ... - Google Books | format = | work = | accessdate = | isbn = 978-3-88763-075-1 | year = 2000 }}</ref><ref name=DictPharmAgents>{{cite book | url = https://books.google.com/books?id=A0THacd46ZsC&q=Indeloxazine#v=snippet&q=Indeloxazine&f=false | title = Dictionary of pharmacological agents - Google Books | format = | work = | accessdate = | isbn = 978-0-412-46630-4 | author1 = r Ganellin | first1 = C | last2 = j Triggle | first2 = D | last3 = MacDonald | first3 = F. | year = 1997 }}</ref> It was marketed from 1988<ref name=DictPharmAgents/> to 1998, when it was removed from the market reportedly for lack of effectiveness.<ref name=Hayashi>{{cite journal|last1=Hayashi|first1=K|last2=Hashimoto|first2=K|last3=Yanagi|first3=M|last4=Umeda|first4=T|last5=Hama|first5=R|title=Drug approval in Japan questioned.|journal=Lancet|date=8 August 1998|volume=352|issue=9126|pages=491|pmid=9708787|doi=10.1016/s0140-6736(05)79232-1}}</ref>

Indeloxazine acts as a [[serotonin releasing agent]], [[norepinephrine reuptake inhibitor]], and [[NMDA receptor antagonist]].<ref name="pmid9833647">{{cite journal |vauthors=Yamaguchi T, Ohyama M, Suzuki M | title = Neurochemical and behavioral characterization of potential antidepressant properties of indeloxazine hydrochloride | journal = Neuropharmacology | volume = 37 | issue = 9 | pages = 1169–76 | date= September 1998  | pmid = 9833647 | doi = 10.1016/s0028-3908(98)00009-4| url = http://linkinghub.elsevier.com/retrieve/pii/S0028390898000094|displayauthors=etal}}</ref><ref name="pmid1652446">{{cite journal |vauthors=Kaneko S, Sugimura M, Inoue T, Satoh M | title = Effects of several cerebroprotective drugs on NMDA channel function: evaluation using Xenopus oocytes and [3H]MK-801 binding | journal = European Journal of Pharmacology | volume = 207 | issue = 2 | pages = 119–28 | date = June 1991 | pmid = 1652446 | doi = 10.1016/0922-4106(91)90086-w| url = }}</ref> It has been found to enhance [[acetylcholine]] release in the rat [[forebrain]] through activation of the [[5-HT4 receptor|5-HT<sub>4</sub> receptor]] via its action as a serotonin releasing agent.<ref name="Peñas-CazorlaVilaró2014">{{cite journal|last1=Peñas-Cazorla|first1=Raúl|last2=Vilaró|first2=M. Teresa|title=Serotonin 5-HT4 receptors and forebrain cholinergic system: receptor expression in identified cell populations|journal=Brain Structure and Function|volume=220|issue=6|year=2014|pages=3413–3434|issn=1863-2653|doi=10.1007/s00429-014-0864-z}}</ref><ref name="pmid9453456">{{cite journal |vauthors=Yamaguchi T, Suzuki M, Yamamoto M | title = Facilitation of acetylcholine release in rat frontal cortex by indeloxazine hydrochloride: involvement of endogenous serotonin and 5-HT4 receptors | journal = Naunyn-Schmiedeberg's Archives of Pharmacology | volume = 356 | issue = 6 | pages = 712–20 | date = December 1997 | pmid = 9453456 | doi = 10.1007/pl00005110| url = http://link.springer.de/link/service/journals/00210/bibs/7356006/73560712.htm}}</ref><ref name="pmid8078992">{{cite journal |vauthors=Yamamoto M, Takahashi K, Ohyama M | title = Possible involvement of central cholinergic system in ameliorating effects of indeloxazine, a cerebral activator, on disturbance of learning behavior in rats | journal = Progress in Neuro-psychopharmacology & Biological Psychiatry | volume = 18 | issue = 3 | pages = 603–13 | date = May 1994 | pmid = 8078992 | doi = 10.1016/0278-5846(94)90016-7| url = |display-authors=etal}}</ref> The drug has been found to possess [[nootropic]],<ref name="pmid3219685">{{cite journal |vauthors=Ogawa N, Haba K, Sora YH, Higashida A, Sato H, Ogawa S | title = Comparison of the effects of bifemelane hydrochloride and indeloxazine hydrochloride on scopolamine hydrobromide-induced impairment in radial maze performance | journal = Clinical Therapeutics | volume = 10 | issue = 6 | pages = 704–11 | date = 1988 | pmid = 3219685 | doi = | url = }}</ref><ref name="pmid3627384">{{cite journal |vauthors=Yamamoto M, Shimizu M | title = Cerebral activating properties of indeloxazine hydrochloride | journal = Neuropharmacology | volume = 26 | issue = 7A | pages = 761–70 | date = July 1987 | pmid = 3627384 | doi = 10.1016/0028-3908(87)90239-5 }}</ref> [[neuroprotective]],<ref name="pmid3187197">{{cite journal | vauthors = Ogawa N, Haba K, Yoshikawa H, Ono T, Mizukawa K | title = Comparison of the effects of bifemelane hydrochloride, idebenone and indeloxazine hydrochloride on ischemia-induced depletion of brain acetylcholine levels in gerbils | journal = Res. Commun. Chem. Pathol. Pharmacol. | volume = 61 | issue = 2 | pages = 285–8 | date = 1988 | pmid = 3187197 | doi = | url = }}</ref><ref name="pmid3446040">{{cite journal |vauthors=Yamamoto M, Shimizu M, Sakamoto N, Ohtomo H, Kogure K | title = Protective effects of indeloxazine hydrochloride on cerebral ischemia in animals | journal = Archives Internationales de Pharmacodynamie et de Thérapie | volume = 290 | issue = 1 | pages = 16–24 | date =November  1987 | pmid = 3446040 | doi = | url = }}</ref><ref name="pmid8297184">{{cite journal |vauthors=Shimizu-Sasamata M, Terai M, Harada M, Yamamoto M | title = Anti-hypoxic and anti-ischemic actions of indeloxazine hydrochloride and its optical isomers: possible involvement of cerebral energy metabolism | journal = Archives Internationales de Pharmacodynamie et de Thérapie | volume = 324 | issue = | pages = 33–46 | date = 1993 | pmid = 8297184 | doi = | url = }}</ref><ref name="pmid3592867">{{cite journal |vauthors=Yamamoto M, Shimizu M | title = Effects of indeloxazine hydrochloride (YM-08054) on anoxia | journal = Archives Internationales de Pharmacodynamie et de Thérapie | volume = 286 | issue = 2 | pages = 272–81 | date = April 1987| pmid = 3592867 | doi = | url = }}</ref> [[anticonvulsant]],<ref name="pmid8327550">{{cite journal |vauthors=Nakamura J, Anraku T, Shirouzu M, Iwashita Y, Nakazawa Y | title = Effects of indeloxazine HCl on kindled amygdaloid seizures in rats: comparison with the effects of phenytoin, diazepam, ethanol, and imipramine | journal = Pharmacology, Biochemistry, and Behavior | volume = 45 | issue = 2 | pages = 445–50 | date = June 1993 | pmid = 8327550 | doi = 10.1016/0091-3057(93)90263-s| url = }}</ref> and [[antidepressant]]-like effects in [[animal model]]s.<ref name="pmid4092278" /><ref name="pmid9833647"/>

==References==
{{reflist|30em}}

{{Antidepressants}}
{{Nootropics}}
{{Glutamate receptor modulators}}
{{Monoamine releasing agents}}

[[Category:Abandoned drugs]]
[[Category:Antidepressants]]
[[Category:Indenes]]
[[Category:Morpholines]]
[[Category:NMDA receptor antagonists]]
[[Category:Nootropics]]
[[Category:Norepinephrine reuptake inhibitors]]
[[Category:Phenol ethers]]
[[Category:Serotonin releasing agents]]


{{nervous-system-drug-stub}}